A systematic review and meta-analysis of clinical trials of antibiotic treatment for children with community-acquired pneumonia provides further support for shorter treatment duration, Finnish researchers reported yesterday in Clinical Infectious Diseases.
Michigan's Department of Natural Resources (DNR) yesterday reported three highly pathogenic avian flu cases in red fox kits in three different counties, which came closely on the heels of a similar report from Minnesota.
Over 40% of 79 stool samples from COVID-19 patients admitted to one of four hospitals in Spain contained SARS-CoV-2 RNA but no live virus, suggesting a negligible ability to replicate in this medium and a very low likelihood of fecal-oral viral transmission, finds a study published yesterday in Scientific Reports.
The sensitivity of home rapid antigen COVID-19 tests peaks 4 days after symptom onset, suggesting that a negative antigen test should be followed by a second test in 1 or 2 days, according to a prospective study published today in JAMA Internal Medicine.
Adults hospitalized early in the pandemic with COVID-19 were at more than triple the risk of death than those with influenza, despite the flu patients being older and having more chronic illnesses, according to new data from Spain to be presented at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which starts tomorrow.
Rates of upper airway infections (UAIs) such as croup and bacterial tracheitis among pediatric COVID-19 patients, though low, rose after the Omicron variant became dominant in December 2021, with more than one fifth of hospitalized children with both conditions developing severe illness, estimates a study today in JAMA Pediatrics.
Depression and loneliness have increased among older adults during the pandemic, prompting a need for more coordinated efforts to address the issue, according to a report on social isolation in older Canadians.
Three new studies to be presented at the upcoming European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) conference at the end of the month demonstrate benefits of the antiviral molnupiravir against COVID-19 infections, including evidence that Merck's pill reduces symptoms of the SARS-CoV-2 virus by day 3 of administration.
A study this week in Clinical Infectious Diseases reveals high levels of childhood antibiotic exposure in low- and middle-income countries (LMICs).
Also, WHO experts say polio is still a global public health emergency.